Which of the following are true:

• Digital assets must be reapproved at least every 2 years
• Prior permission from the recipient is required for all digital assets it is required for the proactive ‘pushing’ of promotional material to health professionals
• Digital assets must be approved exactly as they are to appear and in the channel that they will appear
• All digital assets should state the intended audience
• Social media should be avoided by pharmaceutical companies as they cannot control them

With respect to websites which of the following are true:

• They must be protected so that the public cannot access them however the public should not be directed towards promotional content
• A link to the Legal Notice is mandatory
• Cookie notices are mandatory this is the case for EU sites but does not need to be applied globally
• Links to external sites that AZ cannot control are not approvable they are allowed – but judgment needs to be exercised
• They must show the privacy policy

With respect to social media:

• They should be considered as completely accessible to the general public
• Use of the ‘like’ button on Facebook can be seen as endorsement of the content by a company the FDA at least has expressed this view so it would be wise to apply it generally
• Company employees can never use them for personal purposes but they must take care to separate personal use from anything that could be seen as on behalf of the company
• Tweets about therapy areas should be approved by a nominated signatory
• Filters can be used to restrict access so some forms of promotional activity are acceptable this has been tested and the filters on social media to date have been found to be inadequate to prevent general public access, and so in most countries this is not acceptable